THERANEXUS: 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS

THERANEXUS: 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS
Lyon, 7 April 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its results for the year ending 31 December 2020 and presents an update on the progress of its main programs.
Franck Mouthon, Chairman, CEO and co-founder of Theranexus, made the following comments:
"2020 - a year of health crisis - was marked by rigorous expenditure management and cost control. Our cash flow, underpinned by the new equity line implemented in early 2021, is in a good position and will notably ensure our capacity to continue development of the BBDF-101 program. Moreover, we are actively pursuing our partnership discussions for THN102 and restate our confidence in reaching an agreement by the end of the first half of 2021."

Related Keywords

United States ,Paris ,France General ,France ,Portejoie ,Haute Normandie ,French ,Franck Mouthon ,Company Statutory Auditors ,Company Board Of Directors ,Twitter ,Research Tax Credit ,Drug Administration ,Atomic Energy Commission ,Structuring Rd Projects ,Research Tax ,Investigational New Drug ,French Alternative Energies ,Euronext Growth ,ஒன்றுபட்டது மாநிலங்களில் ,பாரிஸ் ,பிரான்ஸ் ஜநரல் ,பிரான்ஸ் ,ஹாட் நார்மண்டி ,பிரஞ்சு ,நிறுவனம் சட்டரீதியான தணிக்கையாளர்கள் ,நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் ,ட்விட்டர் ,ஆராய்ச்சி வரி கடன் ,அணு ஆற்றல் தரகு ,ஆராய்ச்சி வரி ,பிரஞ்சு மாற்று ஆற்றல்கள் ,